[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immutep Ltd ADR (IMMP)

Immutep Ltd ADR (IMMP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 66,863
  • Shares Outstanding, K 147,372
  • Annual Sales, $ 6,690 K
  • Annual Income, $ -39,780 K
  • EBIT $ 0 M
  • EBITDA $ -37 M
  • 60-Month Beta 2.24
  • Price/Sales 10.70
  • Price/Cash Flow N/A
  • Price/Book 1.10
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/29/25
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 390.15% (+88.83%)
  • Historical Volatility 175.74%
  • IV Percentile 82%
  • IV Rank 27.49%
  • IV High 1,253.85% on 02/12/26
  • IV Low 62.69% on 10/03/25
  • Expected Move (DTE 22) 0.2125 (47.59%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 63
  • Volume Avg (30-Day) 96
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 3,968
  • Open Int (30-Day) 4,985
  • Expected Range 0.2340 to 0.6590

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4185 +6.31%
on 05/07/26
0.5647 -21.21%
on 05/15/26
-0.0796 (-15.18%)
since 04/27/26
3-Month
0.2928 +51.95%
on 04/13/26
2.7750 -83.97%
on 03/05/26
-2.3551 (-84.11%)
since 02/27/26
52-Week
0.2928 +51.95%
on 04/13/26
3.5299 -87.40%
on 12/08/25
-1.5451 (-77.64%)
since 05/27/25

Most Recent Stories

More News
IMMP Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Immutep Limited Securities Lawsuit - Contact Levi & Korsinsky

Immutep Projected TACTI-004 Would Deliver a "New Standard of Care" for Lung Cancer Patients. Instead, the Trial Was Stopped for Futility After Enrolling Just Half Its Target, and IMMP Investors Lost $2.28...

IMMP : 0.4420 (-2.58%)
IMMP Shareholder Alert: July 6, 2026 Lead Plaintiff Deadline in Immutep Limited Securities Class Action - Contact The Gross Law Firm

NEW YORK , May 26, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Immutep Limited (NASDAQ: IMMP).

IMMP : 0.4420 (-2.58%)
Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug Candidate On May 5, 2026, a class...

IMMP : 0.4420 (-2.58%)
IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

NEW YORK , May 25, 2026 /PRNewswire/ --

IMMP : 0.4420 (-2.58%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP). Such investors are...

IMMP : 0.4420 (-2.58%)
Lost Money on Immutep Limited (IMMP)? Join Class Action Suit Seeking Recovery - Contact SueWallSt

Immutep's CEO, Chief Scientific Officer, and Chief Medical Officer Face Section 20(a) Control Person Claims After TACTI-004 Trial Collapse Cost Shareholders $2.28 Per Share

IMMP : 0.4420 (-2.58%)
IMMP Deadline Alert: Levi & Korsinsky Reminds Immutep Limited (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Alert: Immutep's 83% Single-Day ADR Collapse Quantifies the Market's Violent Repricing of TACTI-004 Risk That Was Allegedly Known Internally

IMMP : 0.4420 (-2.58%)
IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

NEW YORK , May 19, 2026 /PRNewswire/ -- 

IMMP : 0.4420 (-2.58%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

NEW YORK , May 14, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP).   Such investors...

IMMP : 0.4420 (-2.58%)
IMMP INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Immutep To Contact Him Directly To Discuss Their Options

IMMP : 0.4420 (-2.58%)

Business Summary

Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the...

See More

Key Turning Points

3rd Resistance Point 0.5190
2nd Resistance Point 0.5044
1st Resistance Point 0.4791
Last Price 0.4420
1st Support Level 0.4392
2nd Support Level 0.4246
3rd Support Level 0.3993

See More

52-Week High 3.5299
Fibonacci 61.8% 2.2933
Fibonacci 50% 1.9114
Fibonacci 38.2% 1.5294
Last Price 0.4420
52-Week Low 0.2928

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.